CJC-1295 with DAC
Lyophilized research reference material. Released with a per-lot Certificate of Analysis. For laboratory research use only.
- All products currently listed on this site are for research purposes ONLY.
- All products sold on this website are intended for research and identification purposes only.
- These products are not intended for human dosing, injections, or ingestion.
- Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption.
Research background
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth-hormone-releasing hormone (GHRH 1-29) bearing a maleimido-propionic acid linker that binds serum albumin, markedly extending its circulating half-life. It is studied as a long-acting GHRH-receptor agonist that promotes endogenous, pulsatile growth-hormone release.
Early clinical pharmacology reported sustained elevation of GH and IGF-1; it has no approved indication.
Summary of published scientific literature provided for laboratory research reference only. It is not a claim of safety, efficacy, or suitability for any use, and does not describe or recommend any human or veterinary use.
Selected references
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797.
- Jetté L, et al. hGRF(1-29)-albumin bioconjugates activate the GRF receptor. Endocrinology. 2005;146(7):3052-3058.
Trademarks & attribution
CJC-1295 (DAC:GRF) originated at ConjuChem Biotechnologies and has no approved trademarked drug product. Catalyst Research Labs is not affiliated with that organization. Supplied as reference material only.
